Clinical Trials Logo

Transplant Rejection clinical trials

View clinical trials related to Transplant Rejection.

Filter by:
  • None
  • Page 1

NCT ID: NCT05156710 Recruiting - Clinical trials for Transplant Rejection

BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)

Start date: June 9, 2022
Phase: Phase 2
Study type: Interventional

Primary Objectives: - Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR - Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: - To assess the overall efficacy of BIVV020 in prevention or treatment of AMR - To characterize the safety and tolerability of BIVV020 in kidney transplant participants - To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants - To evaluate the immunogenicity of BIVV020

NCT ID: NCT04615221 Recruiting - Clinical trials for Transplant Rejection

Immunological Mechanisms of Rejection in Uterine Transplantation

MARNI
Start date: September 21, 2020
Phase: N/A
Study type: Interventional

The objective of this study is to understand the mechanisms of rejection in uterine transplantation and to search for non-invasive markers of rejection. The biological samples necessary for our research have been or will be collected during procedures (biopsies, smears, vaginal swab, blood tests) carried out as part of the scheduled follow-up of patients. These will be samples whose collection is minimally or not invasive

NCT ID: NCT04046549 Completed - Clinical trials for Kidney Transplantation

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

Start date: October 30, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and tolerability of dual costimulation blockade with VIB4920 in combination of belatacept in adult male or female recipients of a renal allograft from a deceased, living unrelated or human leukocyte antigen (HLA) non-identical living related donor.

NCT ID: NCT03984747 Recruiting - Complications Clinical Trials

Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

SPARO
Start date: September 14, 2018
Phase:
Study type: Observational

This is a multi-center prospective study designed to collect blood samples from transplant patients in order to improve Natera's method for determining allograft rejection status using the donor-derived cell-free DNA analysis, called Prospera.

NCT ID: NCT03582436 Completed - Clinical trials for Kidney Transplantation

Rejection Diagnosis in Kidney Transplants Patients

KTD-innov
Start date: June 25, 2018
Phase:
Study type: Observational

Main objective: To constitute a prospective multicentre French cohort of kidney transplant recipients including clinical, biological and immunological evaluation combined with non-invasive biomarkers in peripheral blood and urine, and gene expression assessment in allograft biopsy in order to increase the performance of rejection diagnosis in kidney transplant patients. the investigators hypothesise that the addition of non-invasive biomarkers and intragraft assessment of gene expression profiles will improve the diagnosis capacity of histology in kidney transplant recipients as it reveals pathophysiological pathways that are not captured by light microscopy.

NCT ID: NCT01766050 Completed - Clinical trials for Transplant Rejection

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

Start date: January 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the effects of belatacept on the pharmacokinetics of caffeine, losartan, omeprazole, dextromethorphan and midazolam

NCT ID: NCT01338779 Completed - Clinical trials for Kidney Transplantation

Study of Tolerant Kidney Transplant Recipients

FACTOR
Start date: May 2004
Phase: N/A
Study type: Observational

The purpose of this multi-center (observational) registry study is to establish a database of clinical and laboratory information that may help to identify any unique characteristics of tolerant participants that differ from participants who reject their kidney after discontinuing immunosuppressive drugs.

NCT ID: NCT01236378 Completed - Clinical trials for Renal Transplantation

Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients

Start date: December 2010
Phase: Phase 1
Study type: Interventional

Sirolimus, 1 mg, white, triangular tablets (Rapamune®) was approved on 03 April 2007 in China for prophylaxis of organ rejection in renal transplantation. A pharmacokinetic (PK) study to be conducted in renal allograft recipients was requested by State Food and Drug Administration (SFDA) to provide further guidance for clinical use. To minimize risk to patients, this study is designed to collect blood PK samples from renal allograft recipients who are currently under sirolimus (1 mg tablets) treatment with or without concomitant medication(s). PK samples will be collected from these patients to characterize the steady state PK of sirolimus during sirolimus maintenance therapy. This study will not involve any changes to the established treatment regimen for the patients who enroll in the study